Ucb (UCB.BR) Osake Kurssi
Ucb Kurssi
Viimeisten 19 vuoden aikana Ucbn liikevaihto kasvoi 6,1 % vuodessa ja ylsi 7,74 Mrd. EUR:een. Osakekohtainen tulos on kasvanut 6,5 % vuodessa viimeisten 19 vuoden aikana. Ucbn nettomarginaali 20,1 % on noussut verrattuna 18,3 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,69 %. Jakosuhde on noin 17 % tuloksesta. Osinko on kasvanut 2,4 % vuodessa viimeisten 19 vuoden aikana. Ucbn 12 kuukauden konsensustavoitehinta on 280,50 EUR, noin yli kurssia 39,0 %. 26 analyytikosta 20 suosittaa ostoa — kokonaiskonsensus on Osta.
Ucb osakekurssi
Ucb liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Ucb -osakkeesta
UCB SA is primarily active in the healthcare and pharmaceutical industries. With a focus on neurology, immunology, and bone health, UCB SA specializes in the research, development, and commercialization of innovative medicines and solutions. As one of the leading companies in the field, UCB SA aims to improve the lives of patients through advancements in therapy and healthcare services.
The main competitors of Ucb SA in the market include pharmaceutical companies such as Pfizer, Novartis, Roche, and Eli Lilly and Company.
The business model of UCB SA revolves around researching, developing, and commercializing innovative medicines and solutions for patients suffering from severe diseases. UCB SA primarily focuses on neurology and immunology, striving to make a meaningful difference in the lives of patients. The company engages in extensive scientific research, collaborations, and partnerships to bring transformative treatment options to market. By combining its expertise in biology and chemistry, UCB SA aims to deliver targeted therapies and enhance patients' overall well-being. UCB SA's commitment to tackling unmet medical needs makes it a leading player in the pharmaceutical industry.
UCB SA, a prominent pharmaceutical company, has a rich history and background. Established in 1928 in Belgium, UCB SA initially focused on industrial chemistry, gradually shifting its focus towards pharmaceuticals. Over the years, UCB SA has become a global biopharmaceutical leader, specializing in neurology and immunology. The company is renowned for its dedication to research and innovation, developing breakthrough treatments for severe diseases such as epilepsy, Parkinson's, and autoimmune disorders. With a commitment to improving patients' lives, UCB SA maintains strong partnerships and invests in cutting-edge advancements. Through its continuous pursuit of excellence, UCB SA consistently delivers innovative solutions, making a positive impact on countless lives worldwide.
UCB SA, a leading global biopharmaceutical company, has achieved several significant milestones over the years. One notable accomplishment is the development and launch of innovative therapies that have contributed to improving the lives of patients worldwide. In recent years, UCB SA has successfully received regulatory approvals for groundbreaking medications, expanding its portfolio across multiple therapeutic areas. Furthermore, the company has forged strategic collaborations and partnerships to enhance its research and development capabilities, aiming to identify novel treatment options for various health conditions. UCB SA's commitment to scientific excellence and patient-centric approach has positioned it as a prominent player in the healthcare industry, driving advancements in medical science and transforming patient care.
UCB SA is primarily present in several countries and regions across the globe. The company has a strong presence in Europe, especially in countries such as Belgium, its home country, as well as France and Germany. Additionally, UCB SA has established a significant presence in other regions including the United States, Canada, and various countries in Latin America. With a diversified global footprint, UCB SA extends its reach to markets in Asia-Pacific, particularly in Japan, China, and South Korea. These strategic geographical locations enhance UCB SA's ability to serve a wide range of patients and healthcare professionals worldwide.
UCB SA represents a strong set of values and a clear corporate philosophy. The company focuses on patient-centricity, innovation, and sustainability. UCB is committed to improving the lives of patients with severe diseases and strives to deliver value through the development of advanced therapies. By embracing open collaboration and putting patients at the center of their activities, UCB fosters a culture of continuous learning and growth. The company's corporate philosophy emphasizes integrity, accountability, and a strong belief in advancing science and healthcare. UCB SA's dedication to its core values is evident in its ongoing pursuit of breakthrough solutions to address unmet medical needs.
Analyytikot asettavat tällä hetkellä Ucb-osakkeelle keskimääräisen tavoitehinnan 275,68 EUR (mediaani: 280,50 EUR), mikä merkitsee +36,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 26 analyytikkoarvioon.
26 analyytikkoa arvioi tällä hetkellä Ucb-osaketta: 20 suosittaa ostoa, 4 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Ucb-yhtiöltä 8,68 Mrd. EUR liikevaihtoa ja 11,90 EUR osakekohtaista tulosta.
Ucb-osake (UCB.BR) on listattuna 9 pörssissä, muun muassa: London (0NZT.L), SIX (Zürich) (UCB.SW), Frankfurt (UNC.F), München (UNC.MU), Düsseldorf (UNC.DU), Wien (UCB.VI).
UCB SA is a global biopharmaceutical company focused on creating value for patients with neurological and immunological diseases. The company originated in Belgium and now has offices and subsidiaries in over 40 countries worldwide. UCB specializes in the research and development of innovative drugs and therapies to help people with severe or life-threatening illnesses. The company operates in three business areas: drug development, biologics manufacturing, and marketing of branded products in the fields of neurology and immunology. UCB's core competencies lie in the discovery, development, and commercialization of drugs that contribute to the treatment of neurological and immunological diseases. UCB's flagship products include Cimzia, Vimpat, and Keppra. The company is also known for products such as Zyrtec, an antiallergic, and Nootropil, a cognitive function-enhancing drug. Cimzia is a drug used to treat Crohn's disease and rheumatoid arthritis and has proven to be highly effective. Vimpat and Keppra are medications used for the treatment of epilepsy and, in some cases, neuropathic pain disorders. UCB operates its own research centers as well as partnerships with universities, research labs, and other companies to develop new drugs and advance science and technology. It employs several thousand employees in areas such as research and development, manufacturing, marketing, and sales. In biologics manufacturing, the company specializes in producing antibodies that help strengthen the immune system to fight diseases. UCB's biologics line consists of four products: Cimzia, Romosozumab, Rozanolixizumab, and Bimekizumab. Biologics manufacturing is a complex and highly specialized process that requires quality control and strict regulatory requirements. UCB markets its pharmaceutical products in over 100 countries worldwide. The company's market presence includes products for the treatment of epilepsy, Crohn's disease, rheumatoid arthritis, osteoporosis, and allergic reactions. The company is working to expand its portfolio with new products tailored to the needs of patients with rare or severe diseases in the coming years. Overall, UCB's business model is focused on the development of innovative drugs and therapies to meet the needs of people with neurological and immunological diseases. The company engages in research and development, manufacturing, and distribution of medications and biologics in a variety of areas. UCB takes pride in offering high-quality and innovative treatment options to patients and their medical professionals to improve their health and quality of life.
odotettu liikevaihto Ucb on 8,68 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Ucb on 2,26 Mrd. EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Ucb:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,96. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Ucb-osakkeen arvostusta.
Ucb:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,42. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Ucb-osakkeen arvostuskennuslukuna.
Ucb:n Eulpool-laatuscore on 7/10.
Ucb:n ISIN on BE0003739530. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Ucb:n WKN on 852738. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Ucb:n ticker on UCB.BR. Tämä pörssinoteeraus käytetään Ucb-osakkeiden kauppaan pörssissä.
Ucb osake
Ucb Ticker
Ucb FIGI
Kaikki tunnusluvut ja syvällinen analyysi Ucb:sta
Meidän osakeanalyysimme Ucb-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Ucb:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: